Review
Biochemistry & Molecular Biology
Demitria M. Vasilatis, Christopher A. Lucchesi, Paramita M. Ghosh
Summary: Dogs naturally develop prostate cancer similar to aggressive forms found in humans. Prostate cancer samples in dogs often lack androgen receptor (AR), which can enhance our understanding of AR-indifferent prostate cancer in humans. This review highlights the molecular similarities between dog and human prostate cancer variants, suggesting the potential use of dogs as pre-clinical animal models for developing new therapies and diagnostics that can benefit both species.
Editorial Material
Cell Biology
Li Xin
Summary: EZH2 has been shown to promote the development of castration-resistant prostate cancer (CRPC) by interacting with the androgen receptor (AR) to reprogram its transcriptional activity, facilitating the transition of CRPC into a lineage infidelity state.
NATURE CELL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Haozhe Zhang, Yi Zhou, Zengzhen Xing, Rajiv Kumar Sah, Junqi Hu, Hailiang Hu
Summary: This review discusses the close relationship between the evolution of prostate cancer and androgen levels and the status of the androgen receptor. It also explores how alterations in androgen metabolism contribute to the resistance to anti-androgen therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Margherita Corti, Stefano Lorenzetti, Alessandro Ubaldi, Romano Zilli, Daniele Marcoccia
Summary: The role of endocrine disruptors in the human prostate gland is overlooked, but they can influence the homeostasis and diseases of the prostate, including prostate cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Tae Jin Kim, Young Hwa Lee, Kyo Chul Koo
Summary: The androgen receptor (AR) plays a crucial role in the development and progression of prostate cancer (PCa), and treatment for hormone-sensitive prostate cancer (HSPC) relies heavily on androgen deprivation therapy (ADT). Despite most patients progressing to castration-resistant prostate cancer (CRPC), studies suggest that manipulating alternative molecular pathways can help improve current treatments and develop novel therapies for CRPC management.
Article
Oncology
Xiaolei Shi, Abderrahman Day, Hannah E. Bergom, Sydney Tape, Sylvan C. Baca, Zoi E. Sychev, Gabrianne Larson, Asha Bozicevich, Justin M. Drake, Nicholas Zorko, Jinhua Wang, Charles J. Ryan, Emmanuel S. Antonarakis, Justin Hwang
Summary: The study identifies B7-H3 as an immune checkpoint overexpressed in prostate cancer, particularly in metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide-resistant mCRPC cells show increased expression of B7-H3, and it is associated with resistance signaling pathways. The gene network of B7-H3 is strongly correlated with androgen receptor (AR) and its co-factors, suggesting potential therapeutic targets for mCRPC.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Zemin Hou, Shengsong Huang, Zhenfei Li
Summary: Androgens are crucial in the development of prostate cancer, and targeting steroidogenesis and the androgen receptor has been effective in delaying disease progression. New generation androgen receptor pathway inhibitors like abiraterone and enzalutamide continue to emphasize the role of the androgen-AR axis, even in cases of resistance. The importance of this axis in managing the disease after resistance to current treatments, particularly in neuroendocrine prostate cancer, remains uncertain.
Article
Medicine, Research & Experimental
Sue Jin Moon, Byong Chang Jeong, Hwa Jin Kim, Joung Eun Lim, Hye-Jeong Kim, Ghee Young Kwon, Joshua A. Jackman, Jeong Hoon Kim
Summary: The study identified BCT as a potent inhibitor targeting both AR-FL and AR-V7 activities in CRPC, effectively suppressing tumor growth and metastasis. Mechanistically, BCT disrupts the interaction of HSP90 with AR-FL/AR-V7, leading to their degradation and showing promising therapeutic potential against CRPC.
Article
Oncology
Cheng Qian, Dan Li, Yu Chen
Summary: The ETS family of proteins plays critical roles in prostate cancer, and gene fusion and overexpression of certain members have been linked to the development of this cancer. This review provides an overview of the discovery, classification, and therapeutic targeting of ETS family members in prostate cancer.
Review
Biochemistry & Molecular Biology
Navid Sobhani, Praveen Kumar Neeli, Alberto D'Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi
Summary: Metastatic prostate cancer is the most common cancer in males with a poor prognosis, and many patients develop the AR-V7 variant. AR-V7 acts as a transcription factor in the nucleus, repressing crucial tumor suppressor genes. Anti-AR-V7 drugs show promise for this subset of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Zhao Wei, Song Wang, Yaning Xu, Wenzheng Wang, Fraser Soares, Musaddeque Ahmed, Ping Su, Tingting Wang, Elias Orouji, Xin Xu, Yong Zeng, Sujun Chen, Xiaoyu Liu, Tianwei Jia, Zhaojian Liu, Lutao Du, Yunshan Wang, Shaoyong Chen, Chuanxin Wang, Housheng Hansen He, Haiyang Guo
Summary: This study reveals that MYC interacts with CTCF protein and rewires the chromatin architecture in prostate cancer by modifying CTCF-mediated chromatin looping. MYC colocalizes with CTCF at certain genomic sites, enhancing CTCF occupancy and promoting CTCF-mediated chromatin looping, which disrupts the enhancer-promoter loops of genes related to neuroendocrine lineage plasticity.
NATURE COMMUNICATIONS
(2023)
Review
Medicine, Research & Experimental
Joanna Dulinska-Litewka, Dominik Felkle, Kacper Dykas, Zuzanna Handziuk, Marta Krzysztofik, Bartosz Gasiorkiewicz
Summary: The role of cyclins in hormone-dependent neoplasms, especially breast cancer, is crucial. However, cyclins in prostate cancer are less studied, particularly the role of other cyclins that requires further investigation. Recent studies have shown that cyclins not only regulate the cell cycle but also interact with other signaling pathways. The androgen signaling axis plays a significant role in prostate cancer progression and interferes with cyclin pathways.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Xu Li, Shu Zhuo, Yong Suk Cho, Yuchen Liu, Yingzi Yang, Jian Zhu, Jin Jiang
Summary: Hippo signaling inhibits the oncogenic potential of YAP/TAZ-TEAD transcriptional complex, restricting tumor growth. In AR-positive prostate cancer, YAP acts as a tumor suppressor by counteracting TEAD-mediated AR signaling. YAP competes with AR for TEAD binding, disrupting AR-TEAD interaction and preventing TEAD from promoting AR signaling. Targeting the Hippo signaling pathway may provide a therapeutic opportunity to treat therapy resistant AR variants-driven prostate cancer.
Article
Cell Biology
Katie Joanna Miller, Mohammad Asim
Summary: The androgen receptor (AR) signalling pathway plays a key role in prostate cancer. Upstream kinases promote AR signalling, while other kinases are regulated by AR. These kinases represent potential therapeutic targets for PCa.
Article
Biochemistry & Molecular Biology
Dhirodatta Senapati, Vikas Sharma, Santosh Kumar Rath, Uddipak Rai, Naresh Panigrahi
Summary: The article discusses the role of the androgen receptor in prostate cancer and the mechanisms of resistance. It highlights the plasticity of AR-DNA binding and emphasizes the importance of developing alternative strategies to antagonize AR activity.
Article
Endocrinology & Metabolism
Tomohiko Urano, Masataka Shiraki, Tatsuhiko Kuroda, Shiro Tanaka, Fumihiko Urano, Kazuhiro Uenishi, Satoshi Inoue
JOURNAL OF BONE AND MINERAL METABOLISM
(2018)
Article
Endocrinology & Metabolism
Tomohiko Urano, Masataka Shiraki, Tatsuhiko Kuroda, Shiro Tanaka, Fumihiko Urano, Kazuhiro Uenishi, Satoshi Inoue
JOURNAL OF BONE AND MINERAL METABOLISM
(2018)
Article
Biochemistry & Molecular Biology
Ken-ichi Takayama, Takashi Suzuki, Tomoaki Tanaka, Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kazuhiro Ikeda, Satoshi Inoue
Letter
Geriatrics & Gerontology
Gotaro Kojima, Yu Taniguchi, Steve Iliffe, Tomohiko Urano, Kate Walters
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2019)
Article
Geriatrics & Gerontology
Yohei Sawaya, Masahiro Ishizaka, Akira Kubo, Takahiro Shiba, Tamae Sato, Ko Onoda, Hitoshi Maruyama, Tomohiko Urano
GERIATRICS & GERONTOLOGY INTERNATIONAL
(2020)
Article
Geriatrics & Gerontology
Yumi Umeda-Kameyama, Masashi Kameyama, Taro Kojima, Masaki Ishii, Kiwami Kidana, Mitsutaka Yakabe, Shinya Ishii, Tomohiko Urano, Sumito Ogawa, Masahiro Akishita
GERIATRICS & GERONTOLOGY INTERNATIONAL
(2020)
Article
Multidisciplinary Sciences
Tamaki Hirose, Yohei Sawaya, Takahiro Shiba, Masahiro Ishizaka, Ko Onoda, Akira Kubo, Tomohiko Urano
Summary: Research revealed that women and normal walking speed were independent factors associated with discontinuation of outpatient rehabilitation services due to COVID-19. Additionally, individuals who ceased rehabilitation services exhibited lower levels of exercise and higher feelings of fatigue compared to those who continued.
Article
Geriatrics & Gerontology
Yohei Sawaya, Masahiro Ishizaka, Tamaki Hirose, Takahiro Shiba, Ko Onoda, Akira Kubo, Hitoshi Maruyama, Tomohiko Urano
Summary: This cross-sectional study in community-dwelling Japanese older adults examined the measurement error in handgrip strength and gait speed, providing MDC values that differ by gender and are suitable for judging clinical changes.
Article
Geriatrics & Gerontology
Tomohiko Urano, Masataka Shiraki, Takumi Imai, Norio Iinuma, Tatsuhiko Kuroda, Shiro Tanaka, Mitsuru Saito
Summary: The study aimed to evaluate the impact of AGEs on the history of vascular events in postmenopausal women excluding those with diabetes or renal insufficiency. Serum CML levels were found to be significantly associated with the presence of vascular event history, suggesting a potential role of serum CML in vascular events.
GERIATRICS & GERONTOLOGY INTERNATIONAL
(2021)
Article
Geriatrics & Gerontology
Miyoko Watanabe, Masahiro Ishizaka, Akihiro Yakabi, Masafumi Itokazu, Akira Kubo, Tomohiko Urano
Summary: The study found that between 2006 and 2019, the standing and walking balance of community-dwelling older individuals improved, particularly in women.
GERIATRICS & GERONTOLOGY INTERNATIONAL
(2021)
Article
Endocrinology & Metabolism
Masaki Nakano, Yukio Nakamura, Tomohiko Urano, Akiko Miyazaki, Takako Suzuki, Kazuki Watanabe, Jun Takahashi, Masataka Shiraki
Summary: The study found a significant association between circulating homocysteine and MTHFR C677T variant with the prevalence and progression of spinal OA. These factors could serve as potential interventional targets for preventing and improving clinical outcomes of OA.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Multidisciplinary Sciences
Yohei Sawaya, Takahiro Shiba, Masahiro Ishizaka, Tamaki Hirose, Ryo Sato, Akira Kubo, Tomohiko Urano
Summary: This study aimed to identify the most appropriate parameter for assessing respiratory sarcopenia, and found that MEP may be the best indicator. Measuring MEP is simpler than measuring other respiratory parameters, and can be used for screening respiratory sarcopenia.
Article
Geriatrics & Gerontology
Gotaro Kojima, Yu Taniguchi, Reijiro Aoyama, Tomohiko Urano
Summary: Earlier menopause is significantly associated with a higher risk of developing frailty, while later menopause does not have an impact. This suggests that menopause and its related factors may play an important role in the sex difference in frailty.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2022)
Review
Multidisciplinary Sciences
Gotaro Kojima, Yu Taniguchi, Masanori Iwasaki, Reijiro Aoyama, Tomohiko Urano
Summary: Oral health is crucial for overall health and well-being. Mastication, an important oral function, may deteriorate with age. The existing evidence on the association between masticatory dysfunction and frailty is limited and inconclusive.
Article
Geriatrics & Gerontology
Tamaki Hirose, Yohei Sawaya, Masahiro Ishizaka, Naori Hashimoto, Akira Kubo, Tomohiko Urano
Summary: This study aimed to demonstrate the prevalence of pandemic-associated frailty in Japan, a country with an aging population, by comparing the frailty status before and during the COVID-19 outbreak. The results showed a steady increase in frailty among older adults during the pandemic.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
